181 related articles for article (PubMed ID: 38140828)
21. Pirfenidone Attenuates Renal Tubulointerstitial Fibrosis through Inhibiting miR-21.
Bi L; Huang Y; Li J; Yang X; Hou G; Zhai P; Zhang Q; Alhaji AA; Yang Y; Liu B
Nephron; 2022; 146(1):110-120. PubMed ID: 34724669
[TBL] [Abstract][Full Text] [Related]
22. Knockdown of LncRNA-XIST Suppresses Proliferation and TGF-β1-Induced EMT in NSCLC Through the Notch-1 Pathway by Regulation of miR-137.
Wang X; Zhang G; Cheng Z; Dai L; Jia L; Jing X; Wang H; Zhang R; Liu M; Jiang T; Yang Y; Yang M
Genet Test Mol Biomarkers; 2018 Jun; 22(6):333-342. PubMed ID: 29812958
[TBL] [Abstract][Full Text] [Related]
23. MARVELD3 inhibits the epithelial-mesenchymal transition and cell migration by suppressing the Wnt/β-catenin signaling pathway in non-small cell lung cancer cells.
Li S; Qi S; Li Y; Zhang C; Sun L; Liu C; Wang H
Thorac Cancer; 2023 Apr; 14(12):1045-1058. PubMed ID: 36924014
[TBL] [Abstract][Full Text] [Related]
24. Pirfenidone promotes the levels of exosomal miR-200 to down-regulate ZEB1 and represses the epithelial-mesenchymal transition of non-small cell lung cancer cells.
Liu J; Cao L; Li Y; Deng P; Pan P; Hu C; Yang H
Hum Cell; 2022 Nov; 35(6):1813-1823. PubMed ID: 36002606
[TBL] [Abstract][Full Text] [Related]
25. TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction.
Tirino V; Camerlingo R; Bifulco K; Irollo E; Montella R; Paino F; Sessa G; Carriero MV; Normanno N; Rocco G; Pirozzi G
Cell Death Dis; 2013 May; 4(5):e620. PubMed ID: 23640462
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-422a functions as a tumor suppressor in non-small cell lung cancer through SULF2-mediated TGF-β/SMAD signaling pathway.
Li WQ; Zhang JP; Wang YY; Li XZ; Sun L
Cell Cycle; 2019 Aug; 18(15):1727-1744. PubMed ID: 31204561
[TBL] [Abstract][Full Text] [Related]
27. FMNL1 down-regulation suppresses bone metastasis through reducing TGF-β1 expression in non-small cell lung cancer (NSCLC).
Yang XY; Liao JJ; Xue WR
Biomed Pharmacother; 2019 Sep; 117():109126. PubMed ID: 31387165
[TBL] [Abstract][Full Text] [Related]
28. Geraniin inhibits TGF-β1-induced epithelial-mesenchymal transition and suppresses A549 lung cancer migration, invasion and anoikis resistance.
Ko H
Bioorg Med Chem Lett; 2015 Sep; 25(17):3529-34. PubMed ID: 26169124
[TBL] [Abstract][Full Text] [Related]
29. Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer.
Fujiwara A; Funaki S; Fukui E; Kimura K; Kanou T; Ose N; Minami M; Shintani Y
Sci Rep; 2020 Jul; 10(1):10900. PubMed ID: 32616870
[TBL] [Abstract][Full Text] [Related]
30. Combination Effect of Cilengitide with Erlotinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition in Human Non-Small Cell Lung Cancer Cells.
Jeong J; Kim J
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408781
[TBL] [Abstract][Full Text] [Related]
31. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
[TBL] [Abstract][Full Text] [Related]
32. miR-16 mimics inhibit TGF-β1-induced epithelial-to-mesenchymal transition via activation of autophagy in non-small cell lung carcinoma cells.
Wang H; Zhang Y; Wu Q; Wang YB; Wang W
Oncol Rep; 2018 Jan; 39(1):247-254. PubMed ID: 29138833
[TBL] [Abstract][Full Text] [Related]
33. Dioscin suppresses TGF-β1-induced epithelial-mesenchymal transition and suppresses A549 lung cancer migration and invasion.
Lim WC; Kim H; Kim YJ; Choi KC; Lee IH; Lee KH; Kim MK; Ko H
Bioorg Med Chem Lett; 2017 Aug; 27(15):3342-3348. PubMed ID: 28610976
[TBL] [Abstract][Full Text] [Related]
34. Stereospecific effects of ginsenoside 20-Rg3 inhibits TGF-β1-induced epithelial-mesenchymal transition and suppresses lung cancer migration, invasion and anoikis resistance.
Kim YJ; Choi WI; Jeon BN; Choi KC; Kim K; Kim TJ; Ham J; Jang HJ; Kang KS; Ko H
Toxicology; 2014 Aug; 322():23-33. PubMed ID: 24793912
[TBL] [Abstract][Full Text] [Related]
35. SPARC acts as a mediator of TGF-β1 in promoting epithelial-to-mesenchymal transition in A549 and H1299 lung cancer cells.
Sun W; Feng J; Yi Q; Xu X; Chen Y; Tang L
Biofactors; 2018 Sep; 44(5):453-464. PubMed ID: 30346081
[TBL] [Abstract][Full Text] [Related]
36. Resolvin D1 inhibits TGF-β1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32.
Lee HJ; Park MK; Lee EJ; Lee CH
Int J Biochem Cell Biol; 2013 Dec; 45(12):2801-7. PubMed ID: 24120851
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-527 inhibits TGF-β/SMAD induced epithelial-mesenchymal transition via downregulating SULF2 expression in non-small-cell lung cancer.
Huo W; Zhu XM; Pan XY; Du M; Sun Z; Li ZM
Math Biosci Eng; 2019 May; 16(5):4607-4621. PubMed ID: 31499680
[TBL] [Abstract][Full Text] [Related]
38. Suppression of TGF-β1 enhances chemosensitivity of cisplatin-resistant lung cancer cells through the inhibition of drug-resistant proteins.
Wang J; Chen Y; Xiang F; Li M; Li H; Chi J; Ren K
Artif Cells Nanomed Biotechnol; 2018 Nov; 46(7):1505-1512. PubMed ID: 28918673
[TBL] [Abstract][Full Text] [Related]
39. Altered β1,6-GlcNAc branched N-glycans impair TGF-β-mediated epithelial-to-mesenchymal transition through Smad signalling pathway in human lung cancer.
Li N; Xu H; Fan K; Liu X; Qi J; Zhao C; Yin P; Wang L; Li Z; Zha X
J Cell Mol Med; 2014 Oct; 18(10):1975-91. PubMed ID: 24913443
[TBL] [Abstract][Full Text] [Related]
40. BIX02189 inhibits TGF-β1-induced lung cancer cell metastasis by directly targeting TGF-β type I receptor.
Park SJ; Choi YS; Lee S; Lee YJ; Hong S; Han S; Kim BC
Cancer Lett; 2016 Oct; 381(2):314-22. PubMed ID: 27543359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
